Abstract
A new spirooxindole was designed, synthesized and characterized as dual DNA targeting/CDK2 inhibition and simultaneous mitigation of oxidative stress towards selective NSCLC therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have